Abstract Background Coronavirus disease-2019 (COVID-19) is caused by severe acute
respiratory-syndrome coronavirus-2 that interfaces with the renin-angiotensin-aldosterone
system (RAAS) through angiotensin-converting enzyme 2. This interaction has been
proposed as a potential risk factor in patients treated with RAAS inhibitors. Objectives This
study analyzed whether RAAS inhibitors modify the risk for COVID-19. Methods The
RASTAVI (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and …

Background: The coronavirus disease 2019 (COVID-19) is caused by SARS-CoV2 that
interfaces with the renin-angiotensin-aldosterone system (RAAS) through
angiotensinconverting enzyme 2 (ACE-2). This interaction has been proposed as a potential
risk factor in patients treated with RAAS-inhibitors. Objectives: To analyze if RAAS-inhibitors
modify the risk for COVID-19. Methods: RASTAVI (NCT03201185) is an ongoing
randomized clinical trial randomly allocating Ramipril or control after successful …